Literature DB >> 10722702

New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins.

E C Brinkman-Van der Linden1, A Varki.   

Abstract

The siglecs (sialic acid-binding immunoglobulin superfamily lectins) are immunoglobulin superfamily members recognizing sialylated ligands. Most prior studies of siglec specificities focused on alpha2-3- and alpha2-6-sialyllactos(amin)es and on one or two of the siglecs at a time. Here, we explore several new aspects of specificities of the first six reported siglecs, using sialylated glycans presented in multivalent form, on synthetic polyacrylamide backbones, or on mucin polypeptides. First, we report that binding of siglec-1 (sialoadhesin), siglec-3 (CD33), siglec-4a (myelin-associated glycoprotein), and siglec-5 to alpha2-3 sialyllactosamine is affected markedly by the presence of an alpha1-3-linked fucose. Thus, while siglecs may not interfere with selectin-mediated recognition, fucosylation could negatively regulate siglec binding. Second, in contrast to earlier studies, we find that siglec-3 prefers alpha2-6-sialyllactose. Third, siglec-5 binds alpha2-8-linked sialic acid, making it the siglec least specific for linkage recognition. Fourth, siglecs-2 (CD22), -3, -5, and -6 (obesity-binding protein 1) showed significant binding to sialyl-Tn (Neu5Acalpha2-6-GalNAc), a tumor marker associated with poor prognosis. Fifth, siglec-6 is an exception among siglecs in not requiring the glycerol side chain of sialic acid for recognition. Sixth, all siglecs require the carboxyl group of sialic acid for binding. Finally, the presentation of the sialyl-Tn epitope and/or more extended structures that include this motif may be important for optimal recognition by the siglecs. This was concluded from studies using ovine, bovine, and porcine submaxillary mucins and Chinese hamster ovary cells transfected with ST6GalNAc-I and/or the mucin polypeptide MUC1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722702     DOI: 10.1074/jbc.275.12.8625

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  The glycosynapse.

Authors:  Sen-itiroh Hakomori Si
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

Review 2.  Siglecs in the immune system.

Authors:  P R Crocker; A Varki
Journal:  Immunology       Date:  2001-06       Impact factor: 7.397

Review 3.  Glycosylation defining cancer malignancy: new wine in an old bottle.

Authors:  Senitiroh Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-30       Impact factor: 11.205

Review 4.  Siglecs as sensors of self in innate and adaptive immune responses.

Authors:  James C Paulson; Matthew S Macauley; Norihito Kawasaki
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

5.  Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5.

Authors:  Julie N Pegon; Mohamad Kurdi; Caterina Casari; Soline Odouard; Cécile V Denis; Olivier D Christophe; Peter J Lenting
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 6.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

7.  The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin.

Authors:  Jung Hae Yoon; Kumaran Chandrasekharan; Rui Xu; Matthew Glass; Neha Singhal; Paul T Martin
Journal:  Mol Cell Neurosci       Date:  2009-05-12       Impact factor: 4.314

8.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

9.  Human DC-SIGN binds specific human milk glycans.

Authors:  Alexander J Noll; Ying Yu; Yi Lasanajak; Geralyn Duska-McEwen; Rachael H Buck; David F Smith; Richard D Cummings
Journal:  Biochem J       Date:  2016-03-14       Impact factor: 3.857

Review 10.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.